Saggar Rajeev sold $710K of LQDA
Saggar Rajeev (Chief Medical Officer) sold 9,926 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $0.71M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CMO’s open-market sale size, price range, and post-transaction holdings, which can influence short-term sentiment but does not change fundamentals on its own.
Market read
Use primarily for sentiment/positioning checks, not for re-rating the business.
What to watch
Traders may over-weight insider sales; without accompanying changes in guidance, trial results, or financing, the signal is typically weak.
Background
The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp.
Ticker impact
Liquidia CMO Saggar Rajeev sold 9,926 shares in open-market transactions at about $71.51 per share under a 10b5-1 plan.
Likely limited, with any impact more sentiment-driven than fundamental.
The filing is a routine Form 4 open-market sale by an officer under a pre-arranged 10b5-1 plan, with no new operational, clinical, or financial datapoints provided.
Market effects
Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or clinical changes.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than a bearish view.
Key entities
- issuerLiquidia Corp
Company whose officer transaction is disclosed on Form 4.
- insiderSaggar Rajeev
Chief Medical Officer who sold shares under a 10b5-1 plan.
